Kymera Therapeutics Inc
NASDAQ:KYMR 10:50:30 AM EDT
| Market Cap (Intraday) | 2.92B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $56.09 |
| 50-Day MA | $59.13 |
| 200-Day MA | $53.38 |
Kymera Therapeutics Inc Stock, NASDAQ:KYMR
200 Arsenal Yards Boulevard, Suite 230, Watertown, Massachusetts 02472
United States of America
Phone: +1.857.285.5300
Number of Employees: 75
Description
Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.